CRISPR Therapeutics AG financials
$56.00+3.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.2M | $1.5M | $864.0K | $889.0K | $892.0K | $865.0K | $35.7M | $602.0K | $517.0K | $504.0K | $201.2M | $0.00 |
| Gross profit | $10.2M | $1.5M | $864.0K | $889.0K | $892.0K | $865.0K | $35.7M | $602.0K | $517.0K | $504.0K | $201.2M | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$117.3M | -$130.2M | -$154.8M | -$132.1M | -$229.3M | -$148.4M | -$64.6M | -$110.1M | -$151.3M | -$140.6M | $69.6M | -$132.4M |
| Net income | -$91.2M | -$122.9M | -$130.6M | -$106.4M | -$208.5M | -$136.0M | -$37.3M | -$85.9M | -$126.4M | -$116.6M | $89.3M | -$112.2M |
| Net margin | −895.3% | −8431.5% | −15117.2% | −11973.1% | −23379.9% | −15722.1% | −104.5% | −14276.1% | −24450.3% | −23133.1% | 44.4% | — |
| Diluted EPS | $-0.94 | $-1.28 | $-1.37 | $-1.17 | $-2.40 | $-1.58 | $-0.44 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 |
| EBITDA | -$113.0M | -$125.9M | -$149.1M | -$127.6M | -$224.7M | -$143.7M | -$59.7M | -$105.4M | -$146.4M | -$135.8M | $69.6M | -$127.5M |
| Operating cash flow | -$83.5M | -$108.9M | -$92.6M | -$84.6M | -$113.9M | -$53.9M | -$50.0M | -$106.9M | -$95.6M | $109.8M | -$93.6M | -$40.9M |
| Free cash flow | -$84.1M | -$109.4M | -$93.1M | -$84.7M | -$114.0M | -$54.2M | -$50.3M | -$107.1M | -$96.3M | $109.0M | -$94.3M | -$43.0M |
| Diluted shares | 96.5M | 96.1M | 95.4M | 91.3M | 87.1M | 85.9M | 85.5M | 85.2M | 84.9M | 81.8M | 79.7M | 79.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $291.3M | $423.3M | $347.6M | $286.5M | $193.6M | $235.2M |
| Short-term investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B |
| Total debt | $586.2M | $585.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B |
| Total liabilities | $904.2M | $911.3M | $343.4M | $329.3M | $318.6M | $336.9M |
| Shareholders' equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology